Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of adjunctive KarXT in schizophrenia
2022-001666-35Phase 3Active
- Sponsor
- Karuna Therapeutics
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of xanomeline in schizophrenia, sponsored by Karuna Therapeutics. Primary endpoint: Incidence of treatment-emergent adverse events. Started Oct 2022; status: active.
02
Drugs
xanomeline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2022-001666-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001666-35.